{
  "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5",
  "docSlug": "4230ce80abe7092521a593effe59cbcd",
  "documentTitle": "Oculis | Investor Presentation Deck | 48 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 48,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/36",
  "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5",
  "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json",
  "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.105,
        "w": 0.34,
        "x": 0.577,
        "y": 0.687
      },
      "kind": "callout",
      "text": "Successful Phase 2b will support advancement to Phase 3 while evaluating the potential for a precision medicine for DED",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d17a386d-29ee-4e23-925b-81a1740ddd13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.405,
        "w": 0.48,
        "x": 0.028,
        "y": 0.39
      },
      "kind": "chart",
      "text": "High responders: VAS change from baseline >20\n# subj. (%) VAS >20\nOCS-02 12 (18%)\nVehicle 3 (5%)\n*p=0.018",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d90ef8eb-f6c8-479f-b560-f1ed5096cc93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.119,
        "x": 0.853,
        "y": 0.04
      },
      "kind": "image",
      "text": "Oculis",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bebd5cfa-5c04-405b-aad7-99207bc895cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.36,
        "w": 0.34,
        "x": 0.577,
        "y": 0.28
      },
      "kind": "list",
      "text": "Solid association between gene variants and global ocular discomfort score response at treatment day 29 was tested:\nAmong the gene variants tested, one variant out of 8 showed significant effect on the response to OCS-02\nPatients with this gene variant tended to have larger improvement vs. other p < 0.0001\nOculis is planning to further validate OCS-02 biomarker in the upcoming Phase 2b study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4840539-0f78-41ba-8ac8-d86d668b7510",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.48,
        "x": 0.05,
        "y": 0.269
      },
      "kind": "paragraph",
      "text": "Genetic Biomarker for OCS-02 Response\nPre-specified exploratory pharmacogenetic analysis focused on the genes relevant to TNF pathway and Sjogren's syndrome",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6f325e9-edeb-4644-b4b3-91eb2e7aadfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.505,
        "x": 0.029,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Perez. Presented at ARVO 2021 https://iovs.arvojournals.org/article.aspx?articleid=2774294",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73df7a82-297d-44d5-9b73-5788dc0ec961",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.55,
        "x": 0.029,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "https://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=12:6330343-6331343;v=rs1800693;vdb=variation;vf=760495013",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aee5e086-9bbf-4673-9c2b-19184a72fb49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.89,
        "x": 0.026,
        "y": 0.038
      },
      "kind": "title",
      "text": "OCS-02 | Biomarker Identified for High Responders – Potential upside to de-risk Phase 3 and Precision Medicine Approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "084342f6-42a6-4bce-b25f-17bf37f620b9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "fa6f80b8-0875-45b4-93bf-ec77922eaa74",
      "evidence": "chart/bar-vertical: High responders: VAS change from baseline >20 # subj. (%) VAS >20 OCS-02 12 (18%) Vehicle 3 (5%) *p=0.018",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}